XML 40 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting
12 Months Ended
Jun. 30, 2021
Segment Reporting  
Segment Information

17. Segment Information

The Company’s chief operating decision maker, who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

Aytu manages the Company and aggregated its operational and financial information in accordance with two reportable segments: Aytu BioPharma and Aytu Consumer Health. The Aytu BioPharma segment consists of the Company’s prescription products. The Aytu Consumer Health segment contains the Company’s consumer healthcare products, which was the result of the Innovus Merger. During the year ended June 30, 2021, the Aytu BioPharma

segment recognized a total impairment loss of $12.8 million related to divestiture of the Natesto licensed asset and the write-off of Tuzistra licensed asset (see Note 8).

Select financial information for these segments is as follows:

Year Ended June 30, 

2021

    

2020

(In thousands)

Consolidated revenue:

  

 

  

Aytu BioPharma

$

32,678

$

17,249

Aytu Consumer Health

 

32,954

 

10,383

Consolidated revenue

$

65,632

$

27,632

Consolidated net loss:

 

  

 

  

Aytu BioPharma

$

(50,529)

$

(10,464)

Aytu Consumer Health

 

(7,760)

 

(3,157)

Consolidated net loss

$

(58,289)

$

(13,621)

June 30, 

2021

2020

(In thousands)

Total assets:

 

  

 

  

Aytu BioPharma

$

236,449

$

126,724

Aytu Consumer Health

 

29,219

 

26,569

Consolidated assets

$

265,668

$

153,293